Zentalis Pharmaceuticals (ZNTL) Net Cash Flow (2019 - 2026)

Zentalis Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$4.1 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 150.64% year-over-year to -$4.1 million in Q1 2026; TTM through Mar 2026 was -$10.0 million, a 334.77% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, down 63.95% from the prior year.
• Net Cash Flow declined to -$4.1 million in Q1 2026 per ZNTL's latest filing, from -$3.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $230.3 million in Q2 2023 and bottomed at -$155.8 million in Q3 2023.
• The 5-year median for Net Cash Flow is -$3.1 million (2025), against an average of -$1.6 million.
• Biggest YoY gain for Net Cash Flow was 846.56% in 2023; the steepest drop was 16057.34% in 2023.
• Year by year, Net Cash Flow stood at $518000.0 in 2022, then sank by 16057.34% to -$82.7 million in 2023, then jumped by 91.02% to -$7.4 million in 2024, then jumped by 58.53% to -$3.1 million in 2025, then slumped by 32.11% to -$4.1 million in 2026.
• Per Business Quant, the three latest ZNTL Net Cash Flow figures stand at -$4.1 million (Q1 2026), -$3.1 million (Q4 2025), and $1.5 million (Q3 2025).